This study showed that a high percentage of cHCC-CCA tumors expressed Nestin compared to HCC or iCCA, and positivity of Nestin expression was associated with poor survival rates, suggesting that Nestin could be useful as a novel biomarker for diagnosis testing of cHCC-CCA [27]. This evidence concerns the gene NES and hepatocellular carcinoma.